الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 122 |  |  |
| | | from | 122 | | |
Abstract
The management of both types of lymphoma is dependent upon accurate staging, histological evaluation (of primary masses and bone marrow) and other risk factors (including full blood count, erythrocyte sedimentation rate and serum lactate dehydrogenase) scored together in international prognostic indices. Historically, stage has been determined surgically but this has been replaced by cross-sectional imaging modalities, mainly CT scanning. However, the accuracy of CT in identifying small volume nodal disease, splenic, liver or extra-nodal involvement is unreliable and it is also poor at assessing disease activity when residual masses are present following treatment. Functional imaging techniques, initially using 67Ga, and more recently using PET have been found to be more sensitive than cross-sectional imaging. PET is playing an increasing role in the management of both HD and NHL, offering potential advantages in the accuracy of disease assessment at a number of points in the management pathway. These are in (1) initial staging, (2) the assessment of early response to chemotherapy, (3) follow-up and (4) radiotherapy planning. As with any other nuclear imaging modality, it is very important to recognize artifacts while reading the whole-body PET images for the subsequent correct management of patients. Recognition of artifacts improves the sensitivity and specificity of the study tremendously and reduces the need for further evaluation with other radiologic tests PET scanning can be carried out in lymphoma management using tracers other than FDG such as 11C-methionine and 18F-30 fluorothymidine (FLT) as novel radiotracers for B-cell neoplasias and the promising approaches of somatostatin (sst) receptor–mediated targeting of malignant lymphoma, However these tracers have their own limitations. Conclusion: PET can be used as a valuable tool in management in lymphoma. It can be used in the following aspects: (1) initial staging, (2) the assessment of early response to chemotherapy, (3) follow-up and (4) radiotherapy planning.